Celgene Corp.reported a “significant acceleration in prescriptions” to psoriatic arthritis patients during the third quarter for its oral Otezla (apremilast), a drug that the company has been positioning as one of its next blockbusters.
The phosphodiesterase-4 inhibitor was approved in the U.S. as a twice-daily oral treatment for psoriatic arthritis on March 21, and then on Sept. 23 for psoriasis. It competes with entrenched tumor necrosis factor inhibitors like Amgen Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?